Matthias Müllner

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

Katrin Ramsauer, Michael Schwameis, Christa Firbas et al. · The Lancet Infectious Diseases · 2015 · 233 citations

Veterinary Medicine, Immunology, Infectious Diseases +11

Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial

Roland Tschismarov, Pierre Van Damme, Clara Germain et al. · The Lancet · 2023 · 44 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study

Odile Launay, Cécile Artaud, Marie Lachâtre et al. · EBioMedicine · 2022 · 31 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine

Petra Steppert, Magdalena Mosor, Larissa Stanek et al. · Vaccine · 2022 · 22 citations · Full text

Life Sciences, Biotechnology, Infectious Diseases +17